Coherus Biosciences | CHRS - Operating Expenses


Coherus Biosciences reported $51.83M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 11.69B 6.9B Jun/2026
Baxter International USD 2.68B 3.36B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Fujifilm JPY 825.49B 58.1B Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Merck USD 15.77B 2.4B Jun/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Pacira USD 180.54M 7.79M Jun/2026
Perrigo USD 290.5M 645.1M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026
Zoetis USD 3.15B 85M Jun/2026